Growth Hormone Axis Research Peptides

The short version

AMW Peptides is a reading desk, not a store. It collects what the peer-reviewed literature actually says about three synthetic growth hormone-releasing hormone analogs — sermorelin, CJC-1295, and tesamorelin — that sit at the center of endogenous-GH-stimulation research.

Here is the core idea in plain language. Your pituitary gland makes growth hormone (GH) in pulses, mostly at night, driven by a signal peptide called growth hormone-releasing hormone (GHRH). As people age, those pulses tend to shrink. The three compounds on this desk are synthetic versions — analogs — of that same signaling peptide. Instead of supplying growth hormone directly, they nudge the pituitary to make more of the body's own. A peptide is simply a short chain of amino acids, the same building blocks that make up proteins — just smaller.

The three analogs differ in how long they last, how they were regulated, and how much human evidence backs them. This desk lays out those differences plainly, citing primary sources throughout. We do not sell anything, we do not give medical advice, and we never list a human dose.

What this desk covers

The GH/IGF-1 axis works roughly like this: the hypothalamus sends GHRH to the pituitary, the pituitary releases GH in pulses, and GH drives the liver to produce IGF-1 (insulin-like growth factor-1). Somatostatin, a counter-signal, damps the system between pulses. That feedback loop is the reason GHRH analogs are studied differently from exogenous GH — they stimulate the body's own machinery rather than bypassing it.

The three compounds here each approach that axis from a slightly different angle:

• Sermorelin is the 1-29 N-terminal fragment of human GHRH — the shortest fragment that retains full receptor activity — and the lead compound on this desk. It had an FDA-approved clinical life (for pediatric GH deficiency) before commercial withdrawal in 2008, giving it more regulatory and pharmacological documentation than the others ^[1][4][5].
• CJC-1295 is an engineered long-acting variant: four amino-acid substitutions block enzymatic degradation, and in the DAC form a covalent albumin-binding moiety extends the half-life to days ^[10][11]. It has never been approved anywhere and was reviewed — and not recommended — for compounding by the FDA's Pharmacy Compounding Advisory Committee in 2024.
• Tesamorelin is the most clinically validated. It carries a modified N-terminus that resists DPP-IV cleavage and replicates the full 44-residue GHRH sequence. The FDA approved it in 2010 for one specific indication — HIV-associated lipodystrophy — and the randomized-trial evidence for that indication is the strongest on this desk ^[12][13][14].

Use the compound pages to read the evidence for each, or compare these peptides side by side.

The shared mechanism: upstream, not direct

All three analogs operate at the same upstream step: they bind the GHRH receptor on somatotroph cells in the anterior pituitary and activate the Gs/adenylyl-cyclase/cAMP/PKA signaling cascade, which stimulates the synthesis and pulsatile release of the body's own GH ^[1]. Because they act through the pituitary's normal machinery — and somatostatin feedback is left intact — the pulsatile rhythm of GH secretion tends to be preserved rather than replaced.

That mechanistic distinction from direct GH administration matters, and it is one reason researchers have studied GHRH analogs in contexts where physiologic regulation seemed desirable. A 2025 Nature Reviews Endocrinology review covers the receptor signaling, the GH/IGF-1 downstream effects, and the evidence base for this class in detail ^[1]. Whether the mechanistic advantage translates into a safety or efficacy benefit versus direct GH replacement is a question the literature treats as still open.

What are research peptides?

The compounds on this desk belong to a broader category called research peptides — synthetic amino-acid chains that have been studied in the laboratory, in animals, or in early human trials, but have not been approved by a regulator for general medical use (with the limited exception of tesamorelin's specific HIV indication).

Sellers typically describe research peptides as being for laboratory research only. That framing has a practical meaning: for unapproved compounds like CJC-1295, dosing, long-term safety, and real-world effectiveness in healthy people have not been established in the way that approved drugs have. Where a finding comes from an animal model, we say so. Where the human evidence is limited, we note that too. The goal of this desk is a clear-eyed map of what the evidence actually shows — not a catalog of benefits, not a vendor recommendation, and not medical advice.